nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Teniposide—lymphatic system cancer	0.154	0.296	CbGbCtD
Sitaxentan—CYP2C9—Teniposide—lymphatic system cancer	0.128	0.246	CbGbCtD
Sitaxentan—CYP3A4—Cytarabine—lymphatic system cancer	0.0757	0.145	CbGbCtD
Sitaxentan—CYP3A4—Teniposide—lymphatic system cancer	0.0746	0.143	CbGbCtD
Sitaxentan—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0522	0.1	CbGbCtD
Sitaxentan—CYP3A4—Vincristine—lymphatic system cancer	0.0359	0.0689	CbGbCtD
Sitaxentan—Feeling abnormal—Teniposide—lymphatic system cancer	0.000691	0.00144	CcSEcCtD
Sitaxentan—Stomatitis—Vincristine—lymphatic system cancer	0.000689	0.00144	CcSEcCtD
Sitaxentan—Protein urine present—Methotrexate—lymphatic system cancer	0.000688	0.00144	CcSEcCtD
Sitaxentan—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.000683	0.00143	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000678	0.00142	CcSEcCtD
Sitaxentan—Renal failure—Mitoxantrone—lymphatic system cancer	0.000676	0.00141	CcSEcCtD
Sitaxentan—Nausea—Mechlorethamine—lymphatic system cancer	0.000676	0.00141	CcSEcCtD
Sitaxentan—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000674	0.00141	CcSEcCtD
Sitaxentan—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000674	0.00141	CcSEcCtD
Sitaxentan—Alopecia—Bleomycin—lymphatic system cancer	0.000673	0.0014	CcSEcCtD
Sitaxentan—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000671	0.0014	CcSEcCtD
Sitaxentan—Jaundice—Mitoxantrone—lymphatic system cancer	0.000671	0.0014	CcSEcCtD
Sitaxentan—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000669	0.0014	CcSEcCtD
Sitaxentan—Haemoglobin—Carmustine—lymphatic system cancer	0.000668	0.00139	CcSEcCtD
Sitaxentan—Urticaria—Teniposide—lymphatic system cancer	0.000667	0.00139	CcSEcCtD
Sitaxentan—Herpes simplex—Methotrexate—lymphatic system cancer	0.000665	0.00139	CcSEcCtD
Sitaxentan—Haemorrhage—Carmustine—lymphatic system cancer	0.000664	0.00139	CcSEcCtD
Sitaxentan—Body temperature increased—Teniposide—lymphatic system cancer	0.000663	0.00138	CcSEcCtD
Sitaxentan—Haematuria—Mitoxantrone—lymphatic system cancer	0.000656	0.00137	CcSEcCtD
Sitaxentan—Oedema peripheral—Carmustine—lymphatic system cancer	0.000654	0.00137	CcSEcCtD
Sitaxentan—Dyspepsia—Fludarabine—lymphatic system cancer	0.000649	0.00135	CcSEcCtD
Sitaxentan—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.000648	0.00135	CcSEcCtD
Sitaxentan—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000645	0.00135	CcSEcCtD
Sitaxentan—Decreased appetite—Fludarabine—lymphatic system cancer	0.000641	0.00134	CcSEcCtD
Sitaxentan—Visual impairment—Carmustine—lymphatic system cancer	0.00064	0.00134	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000637	0.00133	CcSEcCtD
Sitaxentan—Fatigue—Fludarabine—lymphatic system cancer	0.000636	0.00133	CcSEcCtD
Sitaxentan—Inflammation—Methotrexate—lymphatic system cancer	0.000632	0.00132	CcSEcCtD
Sitaxentan—Constipation—Fludarabine—lymphatic system cancer	0.000631	0.00132	CcSEcCtD
Sitaxentan—Pain—Fludarabine—lymphatic system cancer	0.000631	0.00132	CcSEcCtD
Sitaxentan—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000629	0.00131	CcSEcCtD
Sitaxentan—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000626	0.00131	CcSEcCtD
Sitaxentan—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.000624	0.0013	CcSEcCtD
Sitaxentan—Respiratory failure—Methotrexate—lymphatic system cancer	0.000624	0.0013	CcSEcCtD
Sitaxentan—Urethral disorder—Vincristine—lymphatic system cancer	0.000622	0.0013	CcSEcCtD
Sitaxentan—Eye disorder—Carmustine—lymphatic system cancer	0.000621	0.0013	CcSEcCtD
Sitaxentan—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000621	0.0013	CcSEcCtD
Sitaxentan—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000619	0.00129	CcSEcCtD
Sitaxentan—Hypersensitivity—Teniposide—lymphatic system cancer	0.000618	0.00129	CcSEcCtD
Sitaxentan—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000618	0.00129	CcSEcCtD
Sitaxentan—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000618	0.00129	CcSEcCtD
Sitaxentan—Flushing—Carmustine—lymphatic system cancer	0.000617	0.00129	CcSEcCtD
Sitaxentan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000615	0.00128	CcSEcCtD
Sitaxentan—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000613	0.00128	CcSEcCtD
Sitaxentan—Anaemia—Bleomycin—lymphatic system cancer	0.000612	0.00128	CcSEcCtD
Sitaxentan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000608	0.00127	CcSEcCtD
Sitaxentan—Asthenia—Teniposide—lymphatic system cancer	0.000602	0.00126	CcSEcCtD
Sitaxentan—Malaise—Bleomycin—lymphatic system cancer	0.000597	0.00125	CcSEcCtD
Sitaxentan—Leukopenia—Bleomycin—lymphatic system cancer	0.000593	0.00124	CcSEcCtD
Sitaxentan—Cardiac disorder—Vincristine—lymphatic system cancer	0.000589	0.00123	CcSEcCtD
Sitaxentan—Alopecia—Carmustine—lymphatic system cancer	0.000587	0.00123	CcSEcCtD
Sitaxentan—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000585	0.00122	CcSEcCtD
Sitaxentan—Body temperature increased—Fludarabine—lymphatic system cancer	0.000583	0.00122	CcSEcCtD
Sitaxentan—Mental disorder—Carmustine—lymphatic system cancer	0.000582	0.00121	CcSEcCtD
Sitaxentan—Vaginal infection—Methotrexate—lymphatic system cancer	0.000578	0.00121	CcSEcCtD
Sitaxentan—Malnutrition—Carmustine—lymphatic system cancer	0.000578	0.00121	CcSEcCtD
Sitaxentan—Angiopathy—Vincristine—lymphatic system cancer	0.000575	0.0012	CcSEcCtD
Sitaxentan—Diarrhoea—Teniposide—lymphatic system cancer	0.000574	0.0012	CcSEcCtD
Sitaxentan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000572	0.00119	CcSEcCtD
Sitaxentan—Chest pain—Bleomycin—lymphatic system cancer	0.000564	0.00118	CcSEcCtD
Sitaxentan—Alopecia—Vincristine—lymphatic system cancer	0.00056	0.00117	CcSEcCtD
Sitaxentan—Discomfort—Bleomycin—lymphatic system cancer	0.000557	0.00116	CcSEcCtD
Sitaxentan—Mental disorder—Vincristine—lymphatic system cancer	0.000556	0.00116	CcSEcCtD
Sitaxentan—Neoplasm—Methotrexate—lymphatic system cancer	0.000554	0.00116	CcSEcCtD
Sitaxentan—Alopecia—Mitoxantrone—lymphatic system cancer	0.000546	0.00114	CcSEcCtD
Sitaxentan—Confusional state—Bleomycin—lymphatic system cancer	0.000545	0.00114	CcSEcCtD
Sitaxentan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000543	0.00113	CcSEcCtD
Sitaxentan—Tremor—Carmustine—lymphatic system cancer	0.000542	0.00113	CcSEcCtD
Sitaxentan—Oedema—Bleomycin—lymphatic system cancer	0.000541	0.00113	CcSEcCtD
Sitaxentan—Infection—Bleomycin—lymphatic system cancer	0.000537	0.00112	CcSEcCtD
Sitaxentan—Anaemia—Carmustine—lymphatic system cancer	0.000534	0.00112	CcSEcCtD
Sitaxentan—Vomiting—Teniposide—lymphatic system cancer	0.000533	0.00111	CcSEcCtD
Sitaxentan—Agitation—Carmustine—lymphatic system cancer	0.000531	0.00111	CcSEcCtD
Sitaxentan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000529	0.0011	CcSEcCtD
Sitaxentan—Asthenia—Fludarabine—lymphatic system cancer	0.000529	0.0011	CcSEcCtD
Sitaxentan—Rash—Teniposide—lymphatic system cancer	0.000529	0.0011	CcSEcCtD
Sitaxentan—Dermatitis—Teniposide—lymphatic system cancer	0.000529	0.0011	CcSEcCtD
Sitaxentan—Headache—Teniposide—lymphatic system cancer	0.000526	0.0011	CcSEcCtD
Sitaxentan—Leukopenia—Carmustine—lymphatic system cancer	0.000518	0.00108	CcSEcCtD
Sitaxentan—Anorexia—Bleomycin—lymphatic system cancer	0.000515	0.00108	CcSEcCtD
Sitaxentan—Anaemia—Vincristine—lymphatic system cancer	0.00051	0.00106	CcSEcCtD
Sitaxentan—Agitation—Vincristine—lymphatic system cancer	0.000507	0.00106	CcSEcCtD
Sitaxentan—Hypotension—Bleomycin—lymphatic system cancer	0.000505	0.00105	CcSEcCtD
Sitaxentan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000505	0.00105	CcSEcCtD
Sitaxentan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000499	0.00104	CcSEcCtD
Sitaxentan—Nausea—Teniposide—lymphatic system cancer	0.000498	0.00104	CcSEcCtD
Sitaxentan—Anaemia—Mitoxantrone—lymphatic system cancer	0.000497	0.00104	CcSEcCtD
Sitaxentan—Vertigo—Vincristine—lymphatic system cancer	0.000496	0.00104	CcSEcCtD
Sitaxentan—Hepatic failure—Methotrexate—lymphatic system cancer	0.000495	0.00103	CcSEcCtD
Sitaxentan—Leukopenia—Vincristine—lymphatic system cancer	0.000494	0.00103	CcSEcCtD
Sitaxentan—Chest pain—Carmustine—lymphatic system cancer	0.000492	0.00103	CcSEcCtD
Sitaxentan—Malaise—Mitoxantrone—lymphatic system cancer	0.000485	0.00101	CcSEcCtD
Sitaxentan—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000481	0.001	CcSEcCtD
Sitaxentan—Confusional state—Carmustine—lymphatic system cancer	0.000476	0.000993	CcSEcCtD
Sitaxentan—Oedema—Carmustine—lymphatic system cancer	0.000472	0.000985	CcSEcCtD
Sitaxentan—Decreased appetite—Bleomycin—lymphatic system cancer	0.00047	0.000981	CcSEcCtD
Sitaxentan—Visual disturbance—Methotrexate—lymphatic system cancer	0.000469	0.00098	CcSEcCtD
Sitaxentan—Infection—Carmustine—lymphatic system cancer	0.000469	0.000979	CcSEcCtD
Sitaxentan—Vomiting—Fludarabine—lymphatic system cancer	0.000469	0.000979	CcSEcCtD
Sitaxentan—Rash—Fludarabine—lymphatic system cancer	0.000465	0.00097	CcSEcCtD
Sitaxentan—Dermatitis—Fludarabine—lymphatic system cancer	0.000465	0.00097	CcSEcCtD
Sitaxentan—Pain—Bleomycin—lymphatic system cancer	0.000462	0.000965	CcSEcCtD
Sitaxentan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000462	0.000964	CcSEcCtD
Sitaxentan—Headache—Fludarabine—lymphatic system cancer	0.000462	0.000964	CcSEcCtD
Sitaxentan—Tachycardia—Carmustine—lymphatic system cancer	0.000461	0.000961	CcSEcCtD
Sitaxentan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000458	0.000955	CcSEcCtD
Sitaxentan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000452	0.000944	CcSEcCtD
Sitaxentan—Oedema—Vincristine—lymphatic system cancer	0.000451	0.00094	CcSEcCtD
Sitaxentan—Anorexia—Carmustine—lymphatic system cancer	0.00045	0.000939	CcSEcCtD
Sitaxentan—Infection—Vincristine—lymphatic system cancer	0.000448	0.000934	CcSEcCtD
Sitaxentan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000446	0.00093	CcSEcCtD
Sitaxentan—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000445	0.000928	CcSEcCtD
Sitaxentan—Confusional state—Mitoxantrone—lymphatic system cancer	0.000442	0.000923	CcSEcCtD
Sitaxentan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000442	0.000922	CcSEcCtD
Sitaxentan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000441	0.000921	CcSEcCtD
Sitaxentan—Hypotension—Carmustine—lymphatic system cancer	0.000441	0.00092	CcSEcCtD
Sitaxentan—Oedema—Mitoxantrone—lymphatic system cancer	0.000439	0.000916	CcSEcCtD
Sitaxentan—Nausea—Fludarabine—lymphatic system cancer	0.000438	0.000914	CcSEcCtD
Sitaxentan—Infection—Mitoxantrone—lymphatic system cancer	0.000436	0.00091	CcSEcCtD
Sitaxentan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00043	0.000897	CcSEcCtD
Sitaxentan—Urticaria—Bleomycin—lymphatic system cancer	0.00043	0.000896	CcSEcCtD
Sitaxentan—Anorexia—Vincristine—lymphatic system cancer	0.000429	0.000896	CcSEcCtD
Sitaxentan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000428	0.000894	CcSEcCtD
Sitaxentan—Body temperature increased—Bleomycin—lymphatic system cancer	0.000427	0.000892	CcSEcCtD
Sitaxentan—Insomnia—Carmustine—lymphatic system cancer	0.000427	0.000891	CcSEcCtD
Sitaxentan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000426	0.000889	CcSEcCtD
Sitaxentan—Hypotension—Vincristine—lymphatic system cancer	0.000421	0.000879	CcSEcCtD
Sitaxentan—Somnolence—Carmustine—lymphatic system cancer	0.00042	0.000876	CcSEcCtD
Sitaxentan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000418	0.000873	CcSEcCtD
Sitaxentan—Ataxia—Methotrexate—lymphatic system cancer	0.000418	0.000873	CcSEcCtD
Sitaxentan—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000411	0.000857	CcSEcCtD
Sitaxentan—Decreased appetite—Carmustine—lymphatic system cancer	0.00041	0.000856	CcSEcCtD
Sitaxentan—Hypotension—Mitoxantrone—lymphatic system cancer	0.00041	0.000856	CcSEcCtD
Sitaxentan—Insomnia—Vincristine—lymphatic system cancer	0.000407	0.00085	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000407	0.00085	CcSEcCtD
Sitaxentan—Constipation—Carmustine—lymphatic system cancer	0.000404	0.000842	CcSEcCtD
Sitaxentan—Pain—Carmustine—lymphatic system cancer	0.000404	0.000842	CcSEcCtD
Sitaxentan—Breast disorder—Methotrexate—lymphatic system cancer	0.000402	0.000839	CcSEcCtD
Sitaxentan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000398	0.000831	CcSEcCtD
Sitaxentan—Decreased appetite—Vincristine—lymphatic system cancer	0.000392	0.000817	CcSEcCtD
Sitaxentan—Somnolence—Mitoxantrone—lymphatic system cancer	0.00039	0.000814	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000389	0.000812	CcSEcCtD
Sitaxentan—Feeling abnormal—Carmustine—lymphatic system cancer	0.000389	0.000812	CcSEcCtD
Sitaxentan—Fatigue—Vincristine—lymphatic system cancer	0.000388	0.000811	CcSEcCtD
Sitaxentan—Asthenia—Bleomycin—lymphatic system cancer	0.000388	0.00081	CcSEcCtD
Sitaxentan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000386	0.000806	CcSEcCtD
Sitaxentan—Constipation—Vincristine—lymphatic system cancer	0.000385	0.000804	CcSEcCtD
Sitaxentan—Pain—Vincristine—lymphatic system cancer	0.000385	0.000804	CcSEcCtD
Sitaxentan—Asthma—Methotrexate—lymphatic system cancer	0.000384	0.000802	CcSEcCtD
Sitaxentan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000381	0.000796	CcSEcCtD
Sitaxentan—Eosinophilia—Methotrexate—lymphatic system cancer	0.000381	0.000794	CcSEcCtD
Sitaxentan—Fatigue—Mitoxantrone—lymphatic system cancer	0.000378	0.00079	CcSEcCtD
Sitaxentan—Pain—Mitoxantrone—lymphatic system cancer	0.000375	0.000783	CcSEcCtD
Sitaxentan—Constipation—Mitoxantrone—lymphatic system cancer	0.000375	0.000783	CcSEcCtD
Sitaxentan—Body temperature increased—Carmustine—lymphatic system cancer	0.000373	0.000779	CcSEcCtD
Sitaxentan—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000369	0.000769	CcSEcCtD
Sitaxentan—Pancytopenia—Methotrexate—lymphatic system cancer	0.000365	0.000762	CcSEcCtD
Sitaxentan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000362	0.000755	CcSEcCtD
Sitaxentan—Dysuria—Methotrexate—lymphatic system cancer	0.000359	0.00075	CcSEcCtD
Sitaxentan—Body temperature increased—Vincristine—lymphatic system cancer	0.000356	0.000743	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000351	0.000732	CcSEcCtD
Sitaxentan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000349	0.000727	CcSEcCtD
Sitaxentan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000348	0.000726	CcSEcCtD
Sitaxentan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000347	0.000724	CcSEcCtD
Sitaxentan—Vomiting—Bleomycin—lymphatic system cancer	0.000344	0.000718	CcSEcCtD
Sitaxentan—Infestation NOS—Methotrexate—lymphatic system cancer	0.000343	0.000715	CcSEcCtD
Sitaxentan—Infestation—Methotrexate—lymphatic system cancer	0.000343	0.000715	CcSEcCtD
Sitaxentan—Rash—Bleomycin—lymphatic system cancer	0.000341	0.000712	CcSEcCtD
Sitaxentan—Dermatitis—Bleomycin—lymphatic system cancer	0.000341	0.000711	CcSEcCtD
Sitaxentan—Asthenia—Carmustine—lymphatic system cancer	0.000339	0.000707	CcSEcCtD
Sitaxentan—Renal failure—Methotrexate—lymphatic system cancer	0.000337	0.000703	CcSEcCtD
Sitaxentan—Stomatitis—Methotrexate—lymphatic system cancer	0.000334	0.000697	CcSEcCtD
Sitaxentan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000333	0.000695	CcSEcCtD
Sitaxentan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000332	0.000693	CcSEcCtD
Sitaxentan—Haematuria—Methotrexate—lymphatic system cancer	0.000327	0.000682	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000324	0.000677	CcSEcCtD
Sitaxentan—Epistaxis—Methotrexate—lymphatic system cancer	0.000323	0.000675	CcSEcCtD
Sitaxentan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000323	0.000675	CcSEcCtD
Sitaxentan—Asthenia—Vincristine—lymphatic system cancer	0.000323	0.000675	CcSEcCtD
Sitaxentan—Diarrhoea—Carmustine—lymphatic system cancer	0.000323	0.000674	CcSEcCtD
Sitaxentan—Nausea—Bleomycin—lymphatic system cancer	0.000321	0.00067	CcSEcCtD
Sitaxentan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000315	0.000657	CcSEcCtD
Sitaxentan—Dizziness—Carmustine—lymphatic system cancer	0.000312	0.000651	CcSEcCtD
Sitaxentan—Haemoglobin—Methotrexate—lymphatic system cancer	0.000309	0.000645	CcSEcCtD
Sitaxentan—Diarrhoea—Vincristine—lymphatic system cancer	0.000308	0.000643	CcSEcCtD
Sitaxentan—Hepatitis—Methotrexate—lymphatic system cancer	0.000308	0.000642	CcSEcCtD
Sitaxentan—Haemorrhage—Methotrexate—lymphatic system cancer	0.000308	0.000642	CcSEcCtD
Sitaxentan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000304	0.000634	CcSEcCtD
Sitaxentan—Urethral disorder—Methotrexate—lymphatic system cancer	0.000302	0.00063	CcSEcCtD
Sitaxentan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0003	0.000627	CcSEcCtD
Sitaxentan—Vomiting—Carmustine—lymphatic system cancer	0.0003	0.000626	CcSEcCtD
Sitaxentan—Dizziness—Vincristine—lymphatic system cancer	0.000298	0.000622	CcSEcCtD
Sitaxentan—Rash—Carmustine—lymphatic system cancer	0.000298	0.000621	CcSEcCtD
Sitaxentan—Dermatitis—Carmustine—lymphatic system cancer	0.000297	0.000621	CcSEcCtD
Sitaxentan—Visual impairment—Methotrexate—lymphatic system cancer	0.000297	0.000619	CcSEcCtD
Sitaxentan—Headache—Carmustine—lymphatic system cancer	0.000296	0.000617	CcSEcCtD
Sitaxentan—Eye disorder—Methotrexate—lymphatic system cancer	0.000288	0.0006	CcSEcCtD
Sitaxentan—Tinnitus—Methotrexate—lymphatic system cancer	0.000287	0.000599	CcSEcCtD
Sitaxentan—Vomiting—Vincristine—lymphatic system cancer	0.000286	0.000598	CcSEcCtD
Sitaxentan—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000286	0.000596	CcSEcCtD
Sitaxentan—Rash—Vincristine—lymphatic system cancer	0.000284	0.000593	CcSEcCtD
Sitaxentan—Dermatitis—Vincristine—lymphatic system cancer	0.000284	0.000592	CcSEcCtD
Sitaxentan—Headache—Vincristine—lymphatic system cancer	0.000282	0.000589	CcSEcCtD
Sitaxentan—Nausea—Carmustine—lymphatic system cancer	0.00028	0.000585	CcSEcCtD
Sitaxentan—Angiopathy—Methotrexate—lymphatic system cancer	0.000279	0.000583	CcSEcCtD
Sitaxentan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000279	0.000582	CcSEcCtD
Sitaxentan—Immune system disorder—Methotrexate—lymphatic system cancer	0.000278	0.00058	CcSEcCtD
Sitaxentan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000277	0.000579	CcSEcCtD
Sitaxentan—Rash—Mitoxantrone—lymphatic system cancer	0.000277	0.000577	CcSEcCtD
Sitaxentan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000276	0.000577	CcSEcCtD
Sitaxentan—Headache—Mitoxantrone—lymphatic system cancer	0.000275	0.000574	CcSEcCtD
Sitaxentan—Alopecia—Methotrexate—lymphatic system cancer	0.000272	0.000567	CcSEcCtD
Sitaxentan—Mental disorder—Methotrexate—lymphatic system cancer	0.00027	0.000563	CcSEcCtD
Sitaxentan—Malnutrition—Methotrexate—lymphatic system cancer	0.000268	0.000559	CcSEcCtD
Sitaxentan—Nausea—Vincristine—lymphatic system cancer	0.000268	0.000559	CcSEcCtD
Sitaxentan—Nausea—Mitoxantrone—lymphatic system cancer	0.000261	0.000544	CcSEcCtD
Sitaxentan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000249	0.000519	CcSEcCtD
Sitaxentan—Anaemia—Methotrexate—lymphatic system cancer	0.000248	0.000517	CcSEcCtD
Sitaxentan—Malaise—Methotrexate—lymphatic system cancer	0.000242	0.000504	CcSEcCtD
Sitaxentan—Vertigo—Methotrexate—lymphatic system cancer	0.000241	0.000502	CcSEcCtD
Sitaxentan—Leukopenia—Methotrexate—lymphatic system cancer	0.00024	0.0005	CcSEcCtD
Sitaxentan—Chest pain—Methotrexate—lymphatic system cancer	0.000228	0.000476	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000226	0.000473	CcSEcCtD
Sitaxentan—Discomfort—Methotrexate—lymphatic system cancer	0.000225	0.00047	CcSEcCtD
Sitaxentan—Confusional state—Methotrexate—lymphatic system cancer	0.00022	0.00046	CcSEcCtD
Sitaxentan—Infection—Methotrexate—lymphatic system cancer	0.000217	0.000453	CcSEcCtD
Sitaxentan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000214	0.000447	CcSEcCtD
Sitaxentan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000214	0.000447	CcSEcCtD
Sitaxentan—Skin disorder—Methotrexate—lymphatic system cancer	0.000212	0.000443	CcSEcCtD
Sitaxentan—Anorexia—Methotrexate—lymphatic system cancer	0.000208	0.000435	CcSEcCtD
Sitaxentan—Hypotension—Methotrexate—lymphatic system cancer	0.000204	0.000426	CcSEcCtD
Sitaxentan—Insomnia—Methotrexate—lymphatic system cancer	0.000198	0.000413	CcSEcCtD
Sitaxentan—Somnolence—Methotrexate—lymphatic system cancer	0.000194	0.000406	CcSEcCtD
Sitaxentan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000192	0.000402	CcSEcCtD
Sitaxentan—Decreased appetite—Methotrexate—lymphatic system cancer	0.00019	0.000397	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000189	0.000394	CcSEcCtD
Sitaxentan—Fatigue—Methotrexate—lymphatic system cancer	0.000188	0.000393	CcSEcCtD
Sitaxentan—Pain—Methotrexate—lymphatic system cancer	0.000187	0.00039	CcSEcCtD
Sitaxentan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00018	0.000376	CcSEcCtD
Sitaxentan—Urticaria—Methotrexate—lymphatic system cancer	0.000174	0.000362	CcSEcCtD
Sitaxentan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000173	0.000361	CcSEcCtD
Sitaxentan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000161	0.000336	CcSEcCtD
Sitaxentan—Asthenia—Methotrexate—lymphatic system cancer	0.000157	0.000327	CcSEcCtD
Sitaxentan—Diarrhoea—Methotrexate—lymphatic system cancer	0.00015	0.000312	CcSEcCtD
Sitaxentan—Dizziness—Methotrexate—lymphatic system cancer	0.000145	0.000302	CcSEcCtD
Sitaxentan—Vomiting—Methotrexate—lymphatic system cancer	0.000139	0.00029	CcSEcCtD
Sitaxentan—Rash—Methotrexate—lymphatic system cancer	0.000138	0.000288	CcSEcCtD
Sitaxentan—Dermatitis—Methotrexate—lymphatic system cancer	0.000138	0.000287	CcSEcCtD
Sitaxentan—Headache—Methotrexate—lymphatic system cancer	0.000137	0.000286	CcSEcCtD
Sitaxentan—Nausea—Methotrexate—lymphatic system cancer	0.00013	0.000271	CcSEcCtD
